Abstract
During their lifetime, 25% of Danes will experience an episode of herpes zoster (HZ). In 15-20% of these 25% HZ will be complicated by postherpetic neuralgia (PHN). The European Medicines Agency has approved two vaccines against HZ, a live attenuated vaccine (ZLV) and a recombinant adjuvanted vaccine (RZV). The efficacy of ZLV against HZ is moderate (51%), age-dependent and declines in 5-8 years. RZV has shown greater-than 90% protection against HZ and PHN across age groups for ≥ 9 years as summarised in this review. Vaccination of everybody > 50 years of age and immunocompromised patients > 18 years of age against HZ with RZV is recommend in several countries and should also be considered in Denmark.
| Bidragets oversatte titel | Vaccination against herpes zoster |
|---|---|
| Originalsprog | Dansk |
| Tidsskrift | Ugeskrift for Laeger |
| Vol/bind | 183 |
| Udgave nummer | 47 |
| ISSN | 0041-5782 |
| Status | Udgivet - 22 nov. 2021 |
Emneord
- Child
- Child, Preschool
- Herpes Zoster Vaccine
- Herpes Zoster/prevention & control
- Herpesvirus 3, Human
- Humans
- Neuralgia, Postherpetic/prevention & control
- Vaccination